Clinical trial on the effects of thalidomide on hemoglobin synthesis in patients with moderate thalassemia intermedia

Ann Hematol. 2018 Oct;97(10):1933-1939. doi: 10.1007/s00277-018-3395-5. Epub 2018 Jun 22.


To investigate the efficacy and safety of thalidomide in patients with thalassemia intermedia (TI). Patients with a confirmed diagnosis of TI who met the trial criteria and signed consent forms were prescribed oral thalidomide 50 mg qn for 3 months from February 2017. Complete blood counts, Hb analysis, and liver and kidney functions were monitored monthly during treatment and any differences were compared before and after treatment. Patients with Hb increments > 2.0 g/dL were termed main responders (MaR), and those with Hb increments between 1.0 and 2.0 g/dL as minor responders (MiR), otherwise they were termed non-responders. Relevance analysis was performed to explore parameters predicting Hb increments after treatment. Adverse effects during treatment were carefully recorded. The overall response rate (ORR = MaR + MiR) and MaR rates were 78.6 and 50% after 1 month of treatment, respectively, and 85.7 and 71.4% after 3 months treatment. At the end of the treatment period, Hb and HbF increased by 2.5 ± 1.8 g/dL and 2.5 ± 1.6 g/dL, while bilirubin, lactate dehydrogenase, and the nucleated red blood cell count (NRBC) were significantly decreased, while the reticulocyte count significantly increased. Correlation analysis showed that the Hb increments correlated significantly with the ratio of HbF before treatment (r = 0.683, P = 0.007) rather than age, Hb, reticulocyte count, and NRBC before treatment. Adverse events during treatment were mild, and drug reduction or withdrawal from the trial was not required. Thalidomide had rapid and significant effects in patients with TI, and also, it is safe and convenient. But larger scale clinical trials will be required to confirm our conclusions.

Trial registration: NCT02995707, .

Keywords: Clinical efficacy; Fetal hemoglobin synthesis; Thalassemia intermedia; Thalidomide.

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Blood Cell Count
  • Female
  • Fetal Hemoglobin / biosynthesis*
  • Fetal Hemoglobin / drug effects*
  • Humans
  • Male
  • Reticulocyte Count
  • Severity of Illness Index
  • Thalidomide / pharmacology
  • Thalidomide / therapeutic use*
  • Treatment Outcome
  • Young Adult
  • beta-Thalassemia / blood
  • beta-Thalassemia / drug therapy*
  • beta-Thalassemia / pathology


  • Thalidomide
  • Fetal Hemoglobin

Associated data